1887

n Obstetrics and Gynaecology Forum - Year-long risk reduction for fractures with a single infusion for postmenopausal osteoporosis : product news

USD

 

Abstract

Novartis South Africa (Pty) Ltd is proud to announce the registration of Aclasta (zoledronic acid 5 mg) for the once yearly treatment of postmenopausal osteoporosis.

Loading

Article metrics loading...

/content/medog/19/2/EJC73331
2009-05-01
2016-12-05
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error